tDCS + Speech-Language Therapy for Aphasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how transcranial direct current stimulation (tDCS) might assist individuals with non-fluent variant primary progressive aphasia (nfvPPA), a condition affecting speech and language. The study compares the effects of tDCS combined with language therapy to language therapy alone, aiming to determine if the combination can slow language decline and improve speech over time. Participants will alternate between active tDCS and a placebo version, with brain imaging assessing changes. Suitable candidates for this trial have been diagnosed with nfvPPA, are right-handed, speak English, and have at least a ninth-grade education. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could enhance future treatment options.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this device is safe for use in language therapy?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe and well-tolerated. In studies involving individuals recovering from stroke-related language problems, tDCS has been used alongside speech therapy to enhance language skills. These studies indicate that tDCS is noninvasive and typically does not cause serious side effects. Most participants experience only minor sensations, such as a slight tingling on the scalp where the electrodes are placed.
While researchers continue to study tDCS, many believe it can be a valuable addition to regular speech therapy. However, experts are still determining the optimal way to use tDCS for maximum benefit. Overall, for those considering participation in a tDCS trial, current research suggests it is a relatively safe option with potential benefits for language improvement.12345Why are researchers excited about this trial?
Unlike traditional treatments for aphasia, which often rely solely on speech-language therapy, this new approach combines it with transcranial direct current stimulation (tDCS). Most treatments focus on intensive language exercises alone, but tDCS works differently by delivering a mild electrical current to the brain, potentially enhancing neural plasticity and improving speech recovery. Researchers are excited because this method targets the brain's ability to reorganize and heal itself, offering a promising path for faster and possibly more effective recovery for individuals with aphasia.
What evidence suggests that tDCS is effective for primary progressive aphasia?
Research has shown that combining a gentle electrical brain stimulation technique called transcranial direct current stimulation (tDCS) with speech-language therapy (SLT) can aid individuals who struggle with speech after a stroke. Studies have found that this combination improves speech and naming skills more effectively than therapy alone. In this trial, participants will receive either active tDCS plus SLT or sham tDCS plus SLT. Specifically, tDCS has helped with naming objects, a common challenge for those with aphasia. Anodal tDCS, a specific type of tDCS, might enhance the effectiveness of language therapy. While results are promising for stroke-related aphasia, researchers continue to investigate the efficacy of tDCS for a different condition called non-fluent variant primary progressive aphasia (nfvPPA).13678
Who Is on the Research Team?
Kyrana Tsapkini, PhD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for right-handed English speakers with at least a 9th grade education, diagnosed with non-fluent variant primary progressive aphasia (nfvPPA) or unclassifiable PPA. Participants must be able to follow directions and not have severe language impairment, other neurological disorders, other language-based learning disorders, or uncorrected visual/hearing impairments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcranial direct current stimulation (tDCS) combined with language therapy, with 10-15 sessions over 1-3 weeks, followed by a 2-month interval before crossover to the other condition.
Follow-up
Participants are monitored for sustained effects of the treatment at 2-week and 2-month intervals post-treatment.
Imaging
Imaging assessments are conducted before and after each treatment phase and at follow-up intervals to evaluate changes in brain connectivity.
What Are the Treatments Tested in This Trial?
Interventions
- tDCS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor